Literature DB >> 8496767

Pharmacokinetics of dapsone in children.

M Mirochnick1, M Michaels, D Clarke, A Breña, A M Regan, S Pelton.   

Abstract

We studied dapsone pharmacokinetics in eight children with compromised immune function who were receiving three different preparations. Peak serum concentration was less than 0.25 microgram/ml after doses of an extemporaneous liquid preparation but ranged from 0.72 to 1.33 micrograms/ml after initial tablet or proprietary liquid doses and 1.48 to 2.48 microgram/ml during long-term proprietary liquid administration. Elimination followed first-order kinetics; the mean elimination half-life was 15.1 hours.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496767     DOI: 10.1016/s0022-3476(06)80033-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

1.  Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children.

Authors:  M Mirochnick; E Cooper; K McIntosh; J Xu; J Lindsey; D Jacobus; L Mofenson; J L Sullivan; W Dankner; L M Frenkel; S Nachman; D W Wara; D Johnson; V R Bonagura; M H Rathore; C K Cunningham; J McNamara
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Penetration of dapsone into pulmonary lining fluid of human immunodeficiency virus type 1-infected patients.

Authors:  M Cruciani; G Gatti; C Mengoli; A Cazzadori; L Lazzarini; F Miletich; M S Graziani; M Malena; D Bassetti
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.

Authors:  Regis Kreitchmann; Brookie M Best; Jiajia Wang; Alice Stek; Edmund Caparelli; D Heather Watts; Elizabeth Smith; David E Shapiro; Steve Rossi; Sandra K Burchett; Elizabeth Hawkins; Mark Byroads; Tim R Cressey; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

Review 4.  Paediatric labelling requirements. Implications for pharmacokinetic studies.

Authors:  J T Wilson; G L Kearns; D Murphy; S J Yaffe
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

5.  Pharmacokinetics of dapsone in human immunodeficiency virus-infected children.

Authors:  G Gatti; A Loy; R Casazza; F Miletich; M Cruciani; D Bassetti
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.